



501 West First Avenue | Columbus, Ohio USA 43215  
Toll Free 800-555-1255 | 614-429-6464 | fax 614-299-8279  
www.abiteccorp.com

Media Release

## **ABITEC Corporation launches new versatile excipient for oral dosage applications**

**Columbus, OH – [February 5, 2019] - ABITEC Corporation continues to add new innovative ingredients that solve the everyday challenges of drug delivery and formulation.**

ABITEC Corporation, a global manufacturer of specialty lipids continues to develop products that meet the ever-evolving demands of the pharmaceutical industry. The challenges of drug formulation and delivery continue to drive the need for lipid-based formulation solutions. ABITEC is continuing to expand its portfolio of excipients to meet these demands and bring new innovative technologies to the pharmaceutical industry.

ABITEC's **CAPMUL® GDB EP/NF** is a monographed glyceryl dibehenate utilized for a range of dosing solutions. CAPMUL GDB EP/NF is a high-purity, highly-reproducible solid lipid excipient which offers good flow and uniform particle size distribution for use in multiple formulations, including tablets, hard gels, softgels, solid lipid nanoparticles, nano-structured lipids, granulations, multi-particulates, extrudates, congealing, and liquids. ABITEC is dedicated to developing high quality lipid excipients for use globally in a range of diversified pharmaceutical applications.

ABITEC's trademarked specialty lipids include Capmul®, Captex®, Caprol®, Acconon®, Sterotex®, Nutri Spense®, Hydro~Kote® and Pureco®. Product application areas vary from pharmaceutical, nutritional and cosmetic products, to the manufacturing of foams, creams, ointments and lotions. These ingredients are produced in the USA under cGMP manufacturing.

### **About ABITEC Corporation**

ABITEC Corporation is part of ABF Ingredients and is headquartered in Columbus, Ohio, USA with two manufacturing sites in the Midwest. ABITEC specializes in the manufacturing and distribution of specialty lipid ingredients for use in the pharmaceutical, nutraceutical, and specialty chemical industries. In addition, ABITEC offers contract and toll manufacturing services for customers looking to develop and manufacture new oleochemical molecules, blends, or toll-manufacture of established products.

### **About ABF Ingredients**

ABF Ingredients is a division of Associated British Foods that focuses on high value ingredients for both food and non-food areas and comprises a range of ingredient companies which include AB Enzymes, Ohly, PGP International, and SPI Pharma. The group has established strong market



positions across a variety of industries, including cereal specialties, enzymes, esters, extruded ingredients, functional polyols, drug delivery systems, specialty lipids, specialty powders, specialty flours, and yeast extracts worldwide.

For further information, please contact:

Amanda Coulter

Manager: Marketing Research and Communications

614-429-6453 | [acoulter@abiteccorp.com](mailto:acoulter@abiteccorp.com)

[www.abiteccorp.com](http://www.abiteccorp.com)

#### **Forward-Looking Statements**

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that the forward-looking information presented in this press release is not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "plan," "seek," "comfortable with," "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.